SCHEMBL2492473

SCHEMBL2492473

Cc1ccn2ncnc2n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
PDE10A Q9Y233 1/20 0.45
KDM4E B2RXH2 7/20 0.42
MAPK1 P28482 3/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ENPP1 P22413 1/20 0.41
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
LMNA P02545 2/20 0.38
PKM P14618 1/20 0.38
CYP1A2 P05177 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
GAA P10253 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9933093 0.75 PDE10A (0.45) ALDH1A1PDE10AKDM4EMAPK1GAA
SCHEMBL8648652 0.75 PDE10A (0.45) ALDH1A1PDE10AKDM4EMAPK1GAA
SCHEMBL5188673 0.75 PDE10A (0.45) ALDH1A1PDE10AKDM4EMAPK1GAA
SCHEMBL362643 0.75 PDE10A (0.45) ALDH1A1PDE10AKDM4EMAPK1HPGD
SCHEMBL5634310 0.75 PDE10A (0.45) ALDH1A1PDE10AKDM4EMAPK1GAA
SCHEMBL13934564 0.75 PDE10A (0.41) ALDH1A1PDE10AKDM4EMAPK1GAA
SCHEMBL12603986 0.75 ALDH1A1 (0.42) ALDH1A1PDE10AKDM4EMAPK1HPGD
SCHEMBL22755250 0.75 PDE10A (0.41) ALDH1A1PDE10AKDM4EMAPK1HPGD
Hydrochloric Acid SCHEMBL31728514 0.73 PDE10A (0.40) ALDH1A1PDE10AKDM4EMAPK1GAA
SCHEMBL3457142 0.72 PDE10A (0.39) ALDH1A1PDE10AKDM4EMAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3080100-B1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2022-11-30 EP disclosed
EP-3287499-B1 A METALLIC NANOPARTICLE DISPERSION AGFA GEVAERT NV (BE) 2021-04-07 EP disclosed
EP-3677583-A1 NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2020-07-08 EP disclosed
CN-109642101-A Metal nanoparticle dispersion 爱克发-格法特公司 2019-04-16 CN disclosed
WO-2019042409-A1 NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION 上海医药集团股份有限公司 2019-03-07 WO disclosed
US-20180200253-A1 Heteroaromatic Compounds and their Use as Dopamine D1 Ligands PFIZER INC. (US) 2018-07-19 US disclosed
US-20170165270-A1 Heteroaromatic Compounds and their Use as Dopamine D1 Ligands PFIZER INC. (US) 2017-06-15 US disclosed
US-9617275-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2017-04-11 US disclosed
US-20160304516-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 Quanticel Pharmaceuticals, Inc. 2016-10-20 US disclosed
US-9430113-B2 Electrically-conductive article with improved bus region EASTMAN KODAK COMPANY (US) 2016-08-30 US disclosed
EP-2009004-A1 NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR Japan Tobacco, Inc. (JP) 2008-12-31 EP disclosed
US-20080081818-A1 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors JAPAN TOBACCO INC. (JP) 2008-04-03 US disclosed
US-20080081818-A1 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors JAPAN TOBACCO INC. (JP) 2008-04-03 US disclosed
WO-2005001568-A1 PHOTOGRAPHIC ELEMENTS CONTAINING A DE-AGGREGATING COMPOUND, DYE-FORMING COUPLER, STABILIZER AND SOLVENT EASTMAN KODAK COMPANY (US) 2005-01-06 WO disclosed
US-5900357-A SUPPORT COVERED ON AT LEAST ONE FACE WITH A LAYER OF SILVER HALIDE EMULSION WHICH CONTAINS AN EFFICIENT AMOUNT OF AT LEAST ONE FREE SPECTRAL SENSITIZING DYE. EASTMAN KODAK COMPANY (US) 1999-05-04 US disclosed
EP-0541067-A1 Heat-developable photographic material FUJI PHOTO FILM CO., LTD. (JP) 1993-05-12 EP disclosed
EP-0541104-A1 Silver halide photographic emulsion and light-sensitive silver halide photographic material making use of the same KONICA CORPORATION (JP) 1993-05-12 EP disclosed
EP-0447534-A1 COLOR PHOTOGRAPHIC RECORDING MATERIAL. EASTMAN KODAK CO (US) 1991-09-25 EP disclosed
EP-0128594-B1 PHOTOGRAPHIC ELEMENTS FOR SILVER SALT DIFFUSION TRANSFER PROCESS FUJI PHOTO FILM CO., LTD. (JP) 1988-01-07 EP disclosed
EP-0064861-B1 SILVER HALIDE PHOTOGRAPHIC MATERIAL KONICA CORPORATION (JP) 1987-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081818-A1 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors HAVCR2, AADAC, DNPEP ALDH1A1 96/4885PDE10A 4089/4885KDM4E 502/4885
US-20180200253-A1 Heteroaromatic Compounds and their Use as Dopamine D1 Ligands COMT, DRD2, NR3C1 ALDH1A1 2144/4885PDE10A 2689/4885KDM4E 3804/4885
US-20170165270-A1 Heteroaromatic Compounds and their Use as Dopamine D1 Ligands ARRB1, DRD3, ADRB1 ALDH1A1 3584/4885PDE10A 1805/4885KDM4E 4598/4885
US-20160304516-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A ALDH1A1 235/4885PDE10A 2944/4885KDM4E 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.